Literature DB >> 16266899

Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia.

Nelly Robillard1, Hélène Cavé, Françoise Méchinaud, Christine Guidal, Francine Garnache-Ottou, Pierre Simon Rohrlich, Hervé Avet-Loiseau, Richard Garand.   

Abstract

BACKGROUND AND OBJECTIVES: Competitive immunoglobulin/T-cell receptor polymerase-chain reaction (PCR) analysis with fluorescent detection is a rapid, cheap and reproducible method for quantifying minimal residual disease (MRD), which is well adapted to the recognition of high-risk childhood acute lymphoblastic leukemia (ALL). We aimed at defining whether flow cytometry (FC) techniques can bypass limitations of PCR for MRD determination. DESIGN AND METHODS: We analyzed 140 remission samples from 91 patients using both competitive PCR amplification of antigen-receptor genes and four-color FC identification of leukemia immunophenotype. These methods were chosen with the aim of detecting at least 0.1% blasts.
RESULTS: MRD was measured using both PCR and FC methods in 123 samples and the two methods provided concordant results in 119 of them (97%). Moreover, three out of the four discordant results appeared minor since MRD was detectable by both methods, but at different levels. In 12 of 13 samples from nine patients, mainly infants with early CD10- and/or t(4;11) B-cell ALL and children with immature T-cell ALL, MRD could be determined using FC whereas PCR failed. Conversely, FC methods were unfeasible due to inappropriate leukemia immunophenotype in three additional children (including two with T-cell ALL) for whom PCR successfully provided MRD results. INTERPRETATION AND
CONCLUSIONS: The MRD results provided by FC techniques were highly concordant with those of competitive PCR. Moreover, the applicability of FC appeared higher in certain ALL subsets, although the appropriateness of this technique in terms of outcome prediction remains to be demonstrated.

Entities:  

Mesh:

Year:  2005        PMID: 16266899

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  8 in total

1.  Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.

Authors:  Izaskun Elorza; Carlos Palacio; Jose Luis Dapena; Laura Gallur; José Sánchez de Toledo; Cristina Díaz de Heredia
Journal:  Haematologica       Date:  2010-02-23       Impact factor: 9.941

Review 2.  Recent developments in the management of T-cell precursor acute lymphoblastic leukemia/lymphoma.

Authors:  Adele K Fielding; Lalita Banerjee; David I Marks
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

3.  Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.

Authors:  W Paul Bowman; Eric L Larsen; Meenakshi Devidas; Stephen B Linda; Laurie Blach; Andrew J Carroll; William L Carroll; D Jeanette Pullen; Jonathan Shuster; Cheryl L Willman; Naomi Winick; Bruce M Camitta; Stephen P Hunger; Michael J Borowitz
Journal:  Pediatr Blood Cancer       Date:  2011-02-25       Impact factor: 3.167

4.  Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia.

Authors:  Misato Kikuchi; Junji Tanaka; Takeshi Kondo; Satoshi Hashino; Masaharu Kasai; Mitsutoshi Kurosawa; Hiroshi Iwasaki; Masanobu Morioka; Tsugumichi Kawamura; Nobuo Masauzi; Takashi Fukuhara; Yasutaka Kakinoki; Hajime Kobayashi; Satoshi Noto; Masahiro Asaka; Masahiro Imamura
Journal:  Int J Hematol       Date:  2010-09-10       Impact factor: 2.490

5.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Authors:  Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta
Journal:  Blood       Date:  2008-04-03       Impact factor: 22.113

Review 6.  How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.

Authors:  Marie C Béné; Jaspal S Kaeda
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

Review 7.  Minimal residual disease in acute lymphoblastic leukemia: optimal methods and clinical relevance, pitfalls and recent approaches.

Authors:  Fatemeh Salari; Mohammad Shahjahani; Saeid Shahrabi; Najmaldin Saki
Journal:  Med Oncol       Date:  2014-10-07       Impact factor: 3.064

Review 8.  Methods of minimal residual disease (MRD) detection in childhood haematological malignancies.

Authors:  Justyna Jółkowska; Katarzyna Derwich; Małgorzata Dawidowska
Journal:  J Appl Genet       Date:  2007       Impact factor: 2.653

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.